× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


× Important note: This Web site presents preliminary results. We are working to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant

colchicine

hydrogen-oxygen nebulizer

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

anti-inflammatory therapies

sodium aescinate

corticosteroids

ciclesonide

inhaled steroids

low-dose corticosteroids

Immunostimulants drugs

anti-PD-1 antibody

convalescent plasma treatment

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

rhG-CSF

vaccines

Immunosuppressants drugs

interleukin-6 inhibitor

sarilumab

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab

ruxolitinib

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

thymosin

antiviral and associated therapy

ASC09/ritonavir

azvudine

baloxavir marboxil

carrimycin

chloroquine and derivatives 1

hydroxychloroquine 1

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

hydroxychloroquine plus macrolides 1

interferon

ivermectin

lopinavir/ritonavir 2

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

oseltamivir plus chloroquin

remdesevir 1

Renin-angiotensin-system-acting agents 6

angiotensin receptor blockers (ARBs)

RAS blocker withdrawal

rhACE2

ritonavir

triazavirin

umifenovir (arbidol) 1

control

prone positioning

miscellaneous

acetylcysteine

alpha lipoic acid

aviptadil

bevacizumab

bismuth

camostat mesilate

continuous positive airway pressure (CPAP)

diammonium glycyrrhizinate

dipyridamol

enoxaparin

levamisole

natural killer (NK) cells

nitric oxide (gas Inhalation or releasing solution)

PUL-042 inhalation solution

stem cells

tradipitant

tranilast

Latest studies

hydroxychloroquine vs. placebo - COVID-19 prophylaxis low risk of bias

  • inconclusive results for: PCR positive or probable Covid-19; PCR confirmed Covid-19

meta-analysis

hydroxychloroquine vs. placebo - COVID-19 prophylaxis low risk of bias

  • inconclusive results for: PCR positive or probable Covid-19; PCR confirmed Covid-19

meta-analysis

PATCH PreP (Abella) , 2020   NCT04329923 yesterday

hydroxychloroquine vs. placebo - COVID-19 prophylaxis some concern in risk of bias

  • inconclusive results for: PCR confirmed infection rate

meta-analysis

Edalatifard , 2020   IRCT20200404046947N1 9 days ago

corticosteroids vs. control - COVID-19 severe or critically high risk of bias

  • suggested 71 % decrease in death but with a low degree of certainty due to high risk of bias

meta-analysis

PLACID , 2020   CTRI/2020/04/024775 3 weeks ago

convalescent plasma treatment vs. control - COVID 19 hospitalized high risk of bias

  • inconclusive results for: 28-day death

meta-analysis

ConPlas-19 , 2020   NCT04345523 4 weeks ago

convalescent plasma treatment vs. standard of care - COVID 19 hospitalized some concern in risk of bias

  • inconclusive results for: time to improvement; overall survival

meta-analysis

COALITION II (Furtado) , 2020   NCT04321278 4 weeks ago

azithromycin vs. control - COVID-19 severe or critically some concern in risk of bias

  • inconclusive results for: Score on six-point ordinal scale at day 15; Death at 29 days

meta-analysis

COVACTA (Rosas) , 2020   NCT04320615 4 weeks ago

tocilizumab vs. placebo - COVID-19 severe or critically some concern in risk of bias

  • inconclusive results for: Clinical status at day 28; Mortality at day 28; Serious infections

meta-analysis

CAPE-COVID , 2020   NCT02517489 4 weeks ago

corticosteroids vs. placebo - COVID-19 severe or critically low risk of bias

  • inconclusive results for: death; nosocomial infections

meta-analysis

REMAP-CAP, fixed 7-day course , 2020   NCT02735707 4 weeks ago

corticosteroids vs. control - COVID-19 severe or critically some concern in risk of bias

  • inconclusive results for: WHO scale at day 14d; death

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons